You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-PD-L1 Antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Unresectable Hepatocellular Carcinoma Trial (Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib)

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • Huaier granule
  • +3 more
  • (no location specified)
Dec 20, 2022

HIV Trial (ASC22 group)

Not yet recruiting
  • HIV Infections
  • ASC22 group
  • (no location specified)
Mar 4, 2022

Advanced Urothelial Carcinoma Trial in Beijing (anti-PD-L1 antibody, albumin bound paclitaxel)

Active, not recruiting
  • Advanced Urothelial Carcinoma
  • anti-PD-L1 antibody
  • albumin bound paclitaxel
  • Beijing, Beijing, China
    Beijing Tumor Hospital
Jan 20, 2022

Cancer Trial in United States (SRK-181, anti-PD-(L)1 antibody therapy)

Recruiting
  • Cancer
  • SRK-181
  • anti-PD-(L)1 antibody therapy
  • Fullerton, California
  • +13 more
Jan 6, 2023

Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

Recruiting
  • Melanoma (Skin)
  • +4 more
  • Bloomington, Minnesota
  • +7 more
Jan 31, 2023

SCLC,Extensive Stage, SLFN11-positive Trial in Worldwide (Niraparib)

Not yet recruiting
  • SCLC,Extensive Stage
  • SLFN11-positive
  • Angers, France
  • +19 more
Jan 30, 2023

NSCLC Trial (BGB-A445, Docetaxel, Tislelizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Sep 6, 2023

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

Recruiting
  • Esophageal Neoplasms
  • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Apr 21, 2022

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
  • Duarte, California
    City of Hope Medical Center
Mar 3, 2022

NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)

Terminated
Has Results
  • Non-small Cell Lung Cancer
  • Saint Petersburg, Florida
  • +2 more
Oct 22, 2022

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

Extensive-stage Small-cell Lung Cancer Trial in Shanghai (ZKAB001, Placebo, Carboplatin)

Recruiting
  • Extensive-stage Small-cell Lung Cancer
  • ZKAB001
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 8, 2021

Sarcoma, Advanced Sarcoma, High Grade Sarcoma Trial in New York (DCC-3014, Avelumab)

Active, not recruiting
  • Sarcoma
  • +6 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 26, 2022

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)

Completed
  • Endometrial Cancer
  • +4 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 3, 2023

Small Cell Lung Cancer Extensive Stage Trial in Jinan, Tianjin, Zhengzhou (IN10018, Tislelizumab, Carboplatin)

Not yet recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Jinan, China
  • +2 more
Sep 10, 2023

Solid Tumors, Adult Trial in Kaunas (NECVAX-NEO1)

Recruiting
  • Solid Tumors, Adult
  • NECVAX-NEO1
  • Kaunas, Lithuania
    Elona Juozaityte
May 16, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Extensive Stage Small Cell Lung Cancer Trial in Shanghai (recombinant anti-PD-L1 mAb injection combined with carboplatin and

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
May 9, 2022

Non Small Cell Lung Cancer Trial in Davis, Orlando, Columbus (ONC-392, Docetaxel)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Davis, California
  • +2 more
Jan 5, 2023